Goldman Sachs’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-20,530
Closed -$10K – 7156
2017
Q2
$10K Hold
20,530
– – ﹤0.01% 6657
2017
Q1
$9K Hold
20,530
– – ﹤0.01% 6627
2016
Q4
$11K Hold
20,530
– – ﹤0.01% 6754
2016
Q3
$11K Buy
20,530
+1,997
+11% +$546 ﹤0.01% 6868
2016
Q2
$4K Buy
+18,533
New +$9.7K ﹤0.01% 6955

Goldman Sachs's AST.WS Position: Q3 2017 in Review

Goldman Sachs sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 20,530 shares — an estimated $10K sold.

Goldman Sachs first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $11K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Goldman Sachs reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 20,530 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $10K.
  • Goldman Sachs first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
  • Goldman Sachs's Asterias Biotherapeutics Warrants position peaked at $11K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.